{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:26:42Z","timestamp":1793647602945,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K02248"],"award-info":[{"award-number":["JP24K02248"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06458"],"award-info":[{"award-number":["JP23K06458"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gastric cancer with peritoneal dissemination (PD) confers poor prognosis and limited treatment options. FGFR2b-targeted therapy has emerged as a potential approach for FGFR2b-positive tumors. However, the expression and amplification status of FGFR2b in PD remains poorly characterized. This study aimed to investigate FGFR2b expression and gene amplification in matched primary tumors and PD tissues from gastric cancer patients, and to evaluate their association with established biomarkers including HER2, CLDN18, and PD-L1. Immunohistochemistry (IHC) for FGFR2b was performed on matched primary and PD tissues from 84 patients.\n                    <jats:italic>FGFR2<\/jats:italic>\n                    FISH was conducted in IHC-positive cases. FGFR2b expression was detected in 7.1% (6\/84) of primary tumors and 4.8% (4\/84) of PD samples. Expression was highly heterogeneous; only one case was FGFR2b-positive in both primary and PD tissues.\n                    <jats:italic>FGFR2<\/jats:italic>\n                    amplification was found in 6 of 10 IHC-positive samples, and not observed in IHC-negative samples. FGFR2b status showed no significant correlation with HER2, CLDN18, or PD-L1. FGFR2b expression in gastric cancer is spatially heterogeneous and discordant between primary tumors and PD. It may be preferable to test both primary tumor and PD tissue, if available, to better identify candidates for FGFR2b-targeted therapy. FGFR2b represents a potential therapeutic target for a subset of PD-positive gastric cancers lacking other biomarker expression.\n                  <\/jats:p>","DOI":"10.1007\/s00428-025-04233-z","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T03:13:58Z","timestamp":1756523638000},"page":"1275-1282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Spatial heterogeneity of FGFR2b in gastric cancer: a comparative analysis of primary tumors and peritoneal dissemination"],"prefix":"10.1007","volume":"488","author":[{"given":"Haruki","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-8380","authenticated-orcid":false,"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"4233_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4233_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10120-016-0658-5","volume":"20","author":"M Inoue","year":"2017","unstructured":"Inoue M (2017) Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer 20:3\u20137. https:\/\/doi.org\/10.1007\/s10120-016-0658-5","journal-title":"Gastric Cancer"},{"key":"4233_CR3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/PAS.0000000000001779","volume":"45","author":"A Iwasaki","year":"2021","unstructured":"Iwasaki A, Ushiku A, Kunita A et al (2021) Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors. Am J Surg Pathol 45:1213\u20131220. https:\/\/doi.org\/10.1097\/PAS.0000000000001779","journal-title":"Am J Surg Pathol"},{"key":"4233_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","volume":"27","author":"H Ogawa","year":"2024","unstructured":"Ogawa H, Abe H, Yagi K, Seto Y, Ushiku T (2024) Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination. Gastric Cancer 27:802\u2013810. https:\/\/doi.org\/10.1007\/s10120-024-01505-6","journal-title":"Gastric Cancer"},{"key":"4233_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang YK et al (2022) Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 23:1430\u20131440. https:\/\/doi.org\/10.1016\/S1470-2045(22)00603-9","journal-title":"Lancet Oncol"},{"key":"4233_CR6","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","volume":"11","author":"M Yashiro","year":"2021","unstructured":"Yashiro M, Kuroda K, Masuda G et al (2021) Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci Rep 11:4698. https:\/\/doi.org\/10.1038\/s41598-021-84107-x","journal-title":"Sci Rep"},{"key":"4233_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00710","volume":"9","author":"SY Rha","year":"2025","unstructured":"Rha SY, Zhang Y, Elme A et al (2025) Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial. JCO Precis Oncol 9:e2400710. https:\/\/doi.org\/10.1200\/PO-24-00710","journal-title":"JCO Precis Oncol"},{"key":"4233_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10120-025-01611-z","volume":"28","author":"H Lee","year":"2025","unstructured":"Lee H, Ryu MH, Lee IS et al (2025) Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer. Gastric Cancer. 28:598. https:\/\/doi.org\/10.1007\/s10120-025-01611-z","journal-title":"Gastric Cancer."},{"key":"4233_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31\u201349. https:\/\/doi.org\/10.1111\/apm.1965.64.1.31","journal-title":"Acta Pathol Microbiol Scand"},{"key":"4233_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C et al (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446\u2013464. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836","journal-title":"J Clin Oncol"},{"key":"4233_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E et al (2019) Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 143:330\u2013337. https:\/\/doi.org\/10.5858\/arpa.2018-0043-OA","journal-title":"Arch Pathol Lab Med"},{"key":"4233_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomized opne-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"4233_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","journal-title":"Lancet"},{"issue":"8","key":"4233_CR14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29(8):2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat Med"},{"key":"4233_CR15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","volume":"29","author":"S Ahn","year":"2016","unstructured":"Ahn S, Lee J, Hong M et al (2016) FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol 29:1095\u20131103. https:\/\/doi.org\/10.1038\/modpathol.2016.96","journal-title":"Mod Pathol"},{"key":"4233_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s10120-024-01516-3","volume":"27","author":"YK Kang","year":"2024","unstructured":"Kang YK, Qin S, Lee KW et al (2024) Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric\/gastroesophageal junction cancer: subgroup of FIGHT final analysis. Gastric Cancer 27:1046\u20131057. https:\/\/doi.org\/10.1007\/s10120-024-01516-3","journal-title":"Gastric Cancer"},{"key":"4233_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/bjc.2013.802","volume":"110","author":"X Su","year":"2014","unstructured":"Su X, Zhan P, Gavine PR et al (2014) FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 110:967\u2013975. https:\/\/doi.org\/10.1038\/bjc.2013.802","journal-title":"Br J Cancer"},{"key":"4233_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H et al (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673\u2013684. https:\/\/doi.org\/10.1136\/gutjnl-2011-301839","journal-title":"Gut"},{"key":"4233_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00428-013-1517-y","volume":"464","author":"G Betts","year":"2014","unstructured":"Betts G, Valentine H, Pritchard S et al (2014) FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virchows Arch 464:145\u2013156. https:\/\/doi.org\/10.1007\/s00428-013-1517-y","journal-title":"Virchows Arch"},{"key":"4233_CR20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.humpath.2011.12.002","volume":"43","author":"EJ Jung","year":"2012","unstructured":"Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH (2012) Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 43:1559\u20131566. https:\/\/doi.org\/10.1016\/j.humpath.2011.12.002","journal-title":"Hum Pathol"},{"key":"4233_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/bjc.2014.61","volume":"110","author":"YJ Liu","year":"2014","unstructured":"Liu YJ, Shen D, Yin X et al (2014) HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer 110:1169\u20131178. https:\/\/doi.org\/10.1038\/bjc.2014.61","journal-title":"Br J Cancer"},{"key":"4233_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/bjc.2011.603","volume":"106","author":"K Matsumoto","year":"2012","unstructured":"Matsumoto K, Arao T, Hamaguchi T et al (2012) FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106:727\u2013732. https:\/\/doi.org\/10.1038\/bjc.2011.603","journal-title":"Br J Cancer"},{"key":"4233_CR23","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1111\/cas.16109","volume":"115","author":"T Hashimoto","year":"2024","unstructured":"Hashimoto T, Nakamura Y, Mishima S et al (2024) Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: a deep dive into its clinical potential. Cancer Sci 115:1622\u20131633. https:\/\/doi.org\/10.1111\/cas.16109","journal-title":"Cancer Sci"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04233-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:54:29Z","timestamp":1781344469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04233-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4233"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04233-z","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the Declaration of Helsinki, and the study protocol was approved by the institutional review board (approval number 10461\u201313). The requirement to obtain written informed consent was waived because this was a retrospective study using existing pathology slides and formalin-fixed, paraffin-embedded blocks. Instead, we used an opt-out approach to provide participants with an informed choice about participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The anti-FGFR2b antibody (clone mFR2-10b) was provided by Daiichi-Sankyo Co., Ltd. This study was carried out independently by the authors, without any involvement from Daiichi Sankyo Co., Ltd. The authors declare no other conflicts of interest related to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}